Goldman Sachs reiterates Acadia Pharmaceuticals stock Sell rating after trial miss
Goldman Sachs reiterated a Sell rating and $17.00 price target on Acadia Pharmaceuticals (ACAD) after its Phase 2 trial for remlifanserin missed the primary endpoint. The stock trades at $22.77, above Goldman's target but below the highest analyst estimate. Acadia plans to continue Phase 3 trials with amendments. Analysts have mixed views, with some revising earnings upwards and others lowering price targets.
How this was made
The 30-second read
Why it matters
The reiterated Sell and $17 target are positioned as a direct response to the Phase 2 primary endpoint miss, potentially shifting near-term expectations for Phase 3 probability-weighted value.
Market read
Traders may reprice ACAD risk after the primary endpoint miss, while monitoring how the amended Phase 3 enrichment strategy changes perceived odds.
What to watch
The article also cites a favorable safety profile (no QT prolongation) and ongoing analyst optimism (some upward earnings revisions, other Buy/Outperform ratings), which may cap downside versus a pure Sell narrative.
Background
Acadia reported Phase 2 results for remlifanserin in Alzheimer’s disease psychosis, with a primary endpoint miss but some secondary/exploratory signals and a Phase 3 plan to continue.
Ticker impact
Goldman reiterated a Sell rating and $17 price target after Acadia’s Phase 2 remlifanserin missed the primary endpoint in Alzheimer’s disease psychosis.
Near-term pressure risk on ACAD as traders weigh the primary endpoint miss against the company’s Phase 3 continuation plan and analyst target dispersion.
The article’s actionable catalyst is the reiterated Sell and lower target tied directly to the Phase 2 primary endpoint miss (p=0.0603) and the amended Phase 3 design removing the 30mg arm.
Market effects
Reinforces risk-off sentiment for CNS/psychiatry biotech programs where primary endpoints miss but companies pivot to secondary/exploratory readouts.
Limited direct regional spillover; primarily affects US biotech sentiment.
Low; clinical-trial readouts and analyst target changes are mostly US-focused for this issuer.
Counterpoint
The Phase 2 miss is borderline (p=0.0603) and Acadia is amending Phase 3 to enrich for modestly severe baseline psychosis, which could improve odds despite the primary endpoint failure.
Key entities
- companyAcadia Pharmaceuticals
NASDAQ-listed biotech developing remlifanserin for Alzheimer’s disease psychosis; plans to continue Phase 3 after Phase 2 primary endpoint miss.
- analyst_firmGoldman Sachs
Reiterated Sell rating and $17 price target for ACAD following Phase 2 trial results.
- drug_candidateremlifanserin
5-HT2A inverse agonist studied in Phase 2; missed primary endpoint at 6 weeks.
